Virtu Financial LLC boosted its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 55.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,900 shares of the biotechnology company's stock after buying an additional 24,331 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Heron Therapeutics worth $189,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Zullo Investment Group Inc. raised its position in shares of Heron Therapeutics by 90.9% during the 1st quarter. Zullo Investment Group Inc. now owns 6,300 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 3,000 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Heron Therapeutics by 43.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,522 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 5,000 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $48,000. Bridgefront Capital LLC bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $60,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $73,000.
Get
Heron Therapeutics alerts:
Wall Street Analyst Weigh In
Several analysts have commented on the stock. Evercore ISI dropped their target price on shares of Heron Therapeutics to $15.00 in a research report on Tuesday, November 15th. Cowen lowered their price objective on shares of Heron Therapeutics to $5.50 in a research report on Monday, August 15th. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, November 9th. Finally, StockNews.com upgraded shares of Heron Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, November 17th.
Heron Therapeutics Price Performance
Shares of NASDAQ HRTX opened at $2.54 on Thursday. The firm has a market cap of $301.98 million, a PE ratio of -1.21 and a beta of 0.88. The company has a current ratio of 2.38, a quick ratio of 1.83 and a debt-to-equity ratio of 6.65. Heron Therapeutics, Inc. has a 1-year low of $2.19 and a 1-year high of $10.46. The company has a fifty day moving average price of $3.47 and a 200 day moving average price of $3.55.
Heron Therapeutics Company Profile
(Get Rating)
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
